A retrospective study on the safety and efficacy of Bendamustine-Brentuximab Vedotin combination in patients with relapsed/refractory Hodgkin lymphoma

Trial Profile

A retrospective study on the safety and efficacy of Bendamustine-Brentuximab Vedotin combination in patients with relapsed/refractory Hodgkin lymphoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top